OPC 1

Drug Profile

OPC 1

Alternative Names: AST-OPC1; GRNOPC 1; hESC-derived oligodendrocyte progenitor cells (OPC) - BioTime; hESC-derived oligodendrocyte progenitor cells (OPC) - Geron/University of California; Oligodendrocyte progenitor cells - Asterias Biotherapeutics; OPC-1; Stem cell therapy - neurodegenerative disorders - Geron

Latest Information Update: 19 Sep 2016

Price : $50

At a glance

  • Originator Geron Corporation
  • Developer Asterias Biotherapeutics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Spinal cord injuries
  • Preclinical Canavan disease; Multiple sclerosis; Stroke
  • Discontinued Alzheimer's disease

Most Recent Events

  • 14 Sep 2016 Interim efficacy and safety data from the phase I/IIa trial in Spinal cord injuries released by Asterias Biotherapeutics
  • 24 May 2016 Asterias Biotherapeutics files for patent protection with United States Patent and Trademark Office (USPTO) for OPC1 in USA
  • 24 May 2016 Interim efficacy data from the phase I/II trial in Spinal cord injuries released by Asterias Biotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top